Mechanism of QHF-cisplatin against hepatocellular carcinoma in a mouse model

Table 2 Tumor quality in mouse xenograft models of hepatocellular carcinoma, inhibition rate and expression of aspartate aminotransferase, Alanine aminotransferase and α-fetoprotein in serum (n = 10, mean ± SD)

Groups	Tumor mass (g)	Inhibition rate	AFP (U/L)	AST (U/L)	ALT (U/L)
Control	/	/	8.2991 ± 0.5020	39.012 ± 2.8909	31.1377 ± 3.7956
Model	0.3836 ± 0.0520	/	10.1266 ± 0.9538f	57.7102 ± 4.2786f	56.8068 ± 2.3614f
QHF	0.2353 ± 0.0709b	38.70%	9.3479 ± 0.9329af	49.0341 ± 1.7405e	29.3448 ± 3.7215b
QHF + DDP	0.1401 ± 0.0145bd	63.50%	9.4775 ± 0.3631af	48.0122 ± 4.751b	50.4108 ± 3.8763f
DDP	0.1819 ± 0.0269b	52.60%	9.3836 ± 0.7724af	40.4485 ± 2.0745a	56.0173 ± 3.1589f

^aP < 0.05,

^bP < 0.01 vs Model group;

^dP < 0.01 vs QHF group;

^eP < 0.05,

^fP < 0.01 vs Control group. Control: Normal control group; Model: Model control group; DDP: Cisplatin group; QHF: QHF group; QHF + DDP: QHF plus cisplatin group. AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; AFP: α-fetoprotein.